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Background: Many young people with major depression fail first-line treatments. Treatment- 
resistant depression has various definitions in the literature but typically assumes nonresponse 
to medication. In young people, cognitive behavioral therapy (CBT) is the recommended first-
line intervention, thus the definition of treatment resistance should be expanded. Therefore, 
our aim was to synthesize the existing evidence of any interventions for treatment-resistant 
depression, broadly defined, in children and adolescents and to investigate the effectiveness of 
CBT in this context.
Methods: We used Cochrane Collaboration methodology, with electronic searches of 
MedlIne, PsycInFO, embase, and the Cochrane depression Anxiety and neurosis Group 
trials registers. Only randomized controlled trials were included, and were assessed for risk of 
bias.   Meta-analysis was undertaken where possible and appropriate.
Results: Of 953 articles retrieved, four trials were eligible for inclusion. For one study, only 
the trial registration document was available, because the study was never completed. All other 
studies were well conducted with a low risk of bias, although one study had a high dropout 
rate. Two studies assessed the effect of adding CBT to medication. While an assertive trial 
of antidepressants does appear to lead to benefit, when compared with placebo, there was no 
  significant advantage, in either study, or in a meta-analysis of data from these trials, that clearly 
demonstrated an additional benefit of CBT. The third trial showed little advantage of a tricyclic 
antidepressant over placebo in the context of an inpatient admission.
Conclusion: Few randomized controlled trials have investigated interventions for treatment-
resistant depression in young people, and results from these show modest benefit from antidepres-
sants with no additional benefit over medication from CBT. Overall, there is a lack of evidence 
about effective interventions to treat young people who have failed to respond to evidence-based 
interventions for depression. Research in this area is urgently required.
Keywords: depressive disorder, treatment-resistant, adolescence, cognitive behavioral therapy, 
systematic review, meta-analysis
Background
depressive disorders in youth are common and debilitating. Point prevalence estimates 
are 2.8% in children (aged under 13 years) and 5.7% adolescents (aged 13–18 years).1 
By the age of 19 years, between a fifth and a quarter of young people have suffered 
from a depressive disorder.2,3 Those who develop a recurrent or chronic disorder 
extending into adulthood are likely to suffer considerable disability and impairment.2,4–6 
The association between depression and completed suicide in young people is of 
particular concern.7–11Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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early onset of depressive disorder often indicates a severe 
illness, with high likelihood of recurrence into   adulthood. 
Approximately 70% of adolescents with diagnosed 
depression will relapse within 5 years and are four times more 
likely to have an adult depressive disorder than adolescents 
who never experience a depressive episode.12,13 The duration 
of a major depressive episode in young people is in the 
range of 6–9 months. However, about 50% of children and 
adolescents remain clinically depressed at 12 months, and 
20%–40% at 24 months.4,14,15
Treatment-resistant or treatment-refractory depression 
is a relatively ill-defined term. Some authors consider 
depression is refractory to treatment after failure to respond 
to one adequate antidepressant trial,16 and others consider it 
as failure to respond to two adequate trials of medication.17 
Most definitions are based on failure to respond to medication 
rather than to psychotherapy or other interventions. There 
is an array of systems that categorize different levels of 
nonresponse to treatment.16 From a client’s perspective, being 
relatively free of symptoms is the ultimate goal of treatment, 
and thus treatment-resistant depression should be defined 
using Frank et al’s18 criteria as a failure to achieve remission, 
which is a period of time during which “the individual is 
asymptomatic (ie, no longer meets syndromal criteria for the 
disorder and has no more than minimal symptoms).”
It must be acknowledged that the treatments currently 
available do not work for all young people.19 Failure to 
respond to first-line treatments with psychotherapy and 
  psychotropic medications is common.20,21 In a review of 
  trials of selective serotonin reuptake inhibitors (SSRIs),22 the 
response rates for those treated with fluoxetine ranged from 
41% to 61%, and remission rates were even lower, ranging 
from 23% to 41%. This means that a large proportion of 
young people receiving recommended pharmacotherapy23 do 
not reach the point of remission, even when taking medication 
according to guideline recommendations. In a meta-analysis 
of trials of psychotherapy, 50.4% of young people had not 
responded to psychotherapy; in the cognitive behavioral 
therapy (CBT) subgroup, the number who did not respond 
was 51.5%.24
Given that depressive disorders are heterogeneous25 
with complex etiology, including biological, psychological, 
and social factors,26–29 in theory, nonmedication strategies 
should have a role in their treatment. Indeed, CBT and 
  interpersonal therapy are recommended as first-line inter-
ventions for the treatment of adolescent depression in the 
national Institute for Health and Clinical excellence guide-
lines in the United Kingdom and in the practice parameters 
for the treatment of depression published by the American 
Academy of Child and Adolescent Psychiatry.23,30,31 CBT 
is the most studied   psychotherapy for young people with 
depression.32,33 CBT was developed on the basis of Beck’s 
cognitive model of depression.34 In CBT, people learn to 
monitor and evaluate their thoughts, identify different levels 
of mood in themselves, recognize thoughts and behaviors 
that have contributed to this mood and learn how to address 
these. Several reviews of CBT have been undertaken, one of 
which showed relatively modest benefits based on continuous 
outcome measures31 and the other showed clear benefit in 
terms of rates of response to the intervention.24 Interpersonal 
conflict is well known as a risk factor for the development 
of depressive disorder in young people,4,29,35 so some CBT 
programs for young people include components addressing 
interpersonal relationships and conflict resolution. A specific 
therapy to address these issues, ie, interpersonal therapy, 
has also been shown to be effective with young people who 
have depression.24
Given the treatment recommendations for children and 
adolescents, it is striking that the definitions of treatment-
resistant depression assume that medication will be the first 
intervention that is trialed, and nonresponse to medication 
is the criterion used to determine treatment resistance. 
In the field of treatment-resistant depression in adults, 
CBT has been investigated as an augmentation strategy.36,37 
The current definitions of treatment resistance should be 
broadened to include failure to respond to any treatment. 
Studies of treatment resistance that include failure to respond 
to psychotherapy and other interventions are needed to 
ensure that a young person failing any first-line treatment 
receives further intervention to prevent the potential long-
term negative impacts of persistent depression.
The aim of this review was to synthesize the   existing 
  evidence of any interventions for treatment-resistant 
  depression in children and adolescents, including   persisting 
depression after psychotherapy or medication. We have 
defined treatment resistance broadly, and included any trial 
that had as one of its aims the treatment of young people with 
treatment-resistant or persistent depression.
Methods
Search strategy
The MedlIne, PsycInFO, and embase databases were 
electronically searched from inception to February 2011. 
MedlIne was searched using the following keywords, and 
where applicable, mapped onto Mesh headings: (“depression” 
or “depressive disorder” or “depressive disorder, major” or Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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“dysthymic disorder” or “mood disorders”) (in major Mesh 
heading field only) And (resistant or refractory) (in title 
field only) and (Adolescent or Adult or Infant+ or Child+ 
or Aged+ or Middle Aged) (in SubMesh heading field only) 
And (clinical trial* or AB clinical trial* or MH clinical 
trial* or Rn clinical trial* random* or AB random* or MH 
random* or Rn random* placebo* or AB placebo* groups) in 
title and publication type fields only. PsycInFO and embase 
were searched using similar search strings, adapted for each 
individual database’s search engine and Mesh headings 
(contact authors for full search strategies).
The Cochrane Collaboration depression Anxiety and 
neurosis Group Clinical Trials Registers (CCdAnCTR) were 
searched. CCdAnCTR-Studies Register was searched using 
the following terms: condition = (depress* and   “treatment 
resistant”) and age group = (child* or adolescent*).
The CCdAnCTR References Register was searched 
using the following terms:
Title/Abstract/Keywords = (depress*) And (adolesc* 
or preadolesc* or pre-adolesc* or boy* or girl* or child* 
or infant* or juvenil* or minors or school* or pediatri* or 
paediatri* or pubescen* or puberty or student* or teen* or 
young or youth* or school* or high-school or “high school” 
or college or undergrad*) And   Free-Text =   (*refractory or 
*  resistan*) OR (chronic* or persist*) OR (recurren* or remiss*) 
OR (nonrespon* or non-respon* or “non respon*”) OR (treat* 
or therap*) and fail*) And #2(link to studies) = empty.
We also searched the references of the studies included 
in the review. The titles and abstracts of all articles retrieved 
in the search were reviewed and the full text was retrieved 
for any articles that appeared to meet the study criteria. Any 
uncertainties over inclusion and exclusion were resolved by 
a discussion between the authors.
inclusion criteria
We included studies that met the following criteria: any 
intervention designed to treat children and/or adolescents 
with treatment-resistant or persistant depression, as defined 
by the authors; study participants aged 4–18 years; and a 
randomized controlled trial design. There were no restrictions 
on language.
Data extraction
Two review authors independently extracted information on 
each study, including characteristics of the design,   participants, 
intervention and comparison groups, information about the 
conduct of the trial in order to assess the risk of bias, and 
outcome data. Any discrepancies were discussed. We assessed 
the risk of bias in included studies using the method followed 
by the Cochrane Collaboration.38 Specifically, assessment 
was made of the conduct of the trial with regard to random 
sequence generation, allocation concealment, blinded assess-
ment of efficacy and adverse outcomes, blinding of care 
providers/participants, whether the number and reasons for 
dropout were reported, if intent-to-treat analysis was done, 
and how studies were funded.
Statistical analysis
The primary outcome from the meta-analysis was a clini-
cally meaningful response to intervention, defined as Clini-
cal Global Impressions (CGI) improvement39 score # 2 
(much or very much improved). This is a commonly used 
definition of response in medication trials of young people 
with depression.4,21,40 Secondary outcomes included reduction 
in clinician-rated and self-rated depressive symptoms 
on   standardized validated symptom measures. Where 
  meta-analysis was appropriate, pooled effect estimates were 
obtained using the meta-analytic standard software used 
by the Cochrane Collaboration, ie, the Review Manager 
statistical software program.42,43
For dichotomous outcomes, including response, the 
risk ratio and the absolute risk reduction were estimated. 
For continuous outcomes, such as depression symptoms, 
where absolute values of post-treatment means and standard 
deviations were given using the same rating scale across 
trials, these were used to calculate the mean difference, and 
where different rating scales were used, the standardized 
mean difference was used.
For all meta-analyses we used the random-effects model 
with a 95% confidence interval (CI). Random-effects mod-
els are in general more conservative than fixed-effects 
models because they take heterogeneity among studies into 
account. With decreasing heterogeneity, the random-effects 
approach moves asymptotically towards a fixed-effects 
model. Where meta-analysis was not appropriate, outcome 
data are   presented in table form and results reported by the 
investigators are discussed in narrative form.
Results
Description of studies
In total, 953 articles were retrieved via the search of 
  electronic databases. Of these, 910 were excluded on the 
basis of title and abstract. Forty-three full text articles were 
retrieved for closer examination, of which 27 were excluded. 
A total of four trials (16 articles) were included, some   
of which had multiple associated secondary publications Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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(see Figure 1).44 For one study,45 only the trial registration 
document is   available because the study was suspended. 
There are no reasons for its suspension provided, nor is it clear 
if recruitment ever started for this trial. The trial was to test 
the effectiveness of fluoxetine augmented with lamotrigine 
compared with sertraline in 13–17-year-olds who had not 
responded to 8 weeks of fluoxetine. This suspended trial will 
not be discussed further.
Of the remaining three studies, one tested the effec-
tiveness of medication alone;46 the Adolescent depres-
sion Antidepressants and Psychotherapy Trial (AdAPT) 
tested the addition of CBT to routine care plus an SSRI 
(primarily fluoxetine) compared with routine care plus an 
SSRI;47 and the Treatment of SSRI-Resistant depression 
in Adolescents (TORdIA) study included four arms, ie, 
venlafaxine alone, an SSRI alone, venlafaxine + CBT, and 
an SSRI + CBT.48
The definition of “treatment resistance” varied from study 
to study. This is likely to have resulted in a difference in the 
severity of depression in participants in the different trials. 
In the medication only trial, young people were required 
to have been referred for a hospital admission due to non-
response to “several psychosocial (group, individual, and 
family) and/or pharmacological inpatient interventions.”46 
Records identified through 
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Figure 1 PRISMA flow diagram of record retrieval and inclusion and exclusion of articles.44
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The mean Hamilton depression Rating Scale (HdRS) score 
for this group of participants was in the severe range at 22.4, 
with a mean index episode duration of 61 weeks. Over 40% 
were considered suicidal, and at least 25% of the partici-
pants had some comorbid disorder, although this is not well 
reported.
In the AdAPT trial, an early presentation of the study 
methodology described its aim as treating “persistent ado-
lescent major depression,”49 with entry criteria being failure 
to respond, in the initial phase of the trial, to two brief initial 
sessions of support and educational interventions with a psy-
chiatrist. The sample included 34 adolescents with “proven 
nonresponse” in that they had failed a trial of psychosocial 
intervention before being referred into the trial. This was a 
pragmatic trial conducted in tertiary specialist mental health 
outpatient clinics and the authors note that “Most participants 
had already been treated and would have received psycho-
social interventions before medication.”47 The Children’s 
depression Rating Scale-Revised (CdRS-R) scores were in 
the moderately severe range, with a median range of index 
episodes of 40 weeks; 88.5% had a comorbid disorder, 
around 40% in each treatment group experienced suicidal 
ideation, and 20% in the fluoxetine group and 12.4% in the 
fluoxetine + CBT group reported a previous suicide attempt 
during their baseline interview.
In the TORdIA study, treatment resistance was defined as 
a failure to respond to at least 8 weeks of treatment with an 
SSRI.48 Participants in this trial also had moderately severe 
depression based on CdRS-R scores, and the median duration 
of the index episode was approximately 68 weeks; 51.5% had 
at least one comorbid disorder and 58.5% had clinically 
significant suicidal ideation.
Both AdAPT and TORdIA were multisite studies, 
recruiting 208 and 334 participants, respectively. The AdAPT 
study recruited via routine outpatient clinical   services, while 
TORdIA recruited via clinical sources and via advertise-
ments. The Birmaher trial46 was a single-site study that 
recruited 27 participants from the inpatient unit in which the 
interventions were delivered.
The mean age of participants in the trials ranged between 
14 years in the AdAPT trial and 16 years in both TORdIA 
and the trial by Birmaher et al.46 In all three trials, the percent-
age of females was approximately 70%. Only AdAPT and 
TORdIA had follow-up assessment, lasting 28 and 24 weeks, 
respectively. Birmaher et al conducted a 10-week acute phase 
with no follow-up reported. Further details of the included 
studies are shown in Table 1.
Methodological quality
Assessment of risk of bias
A description of the conduct of the included trials and 
assessment of the risk of bias is presented in Table 2. 
All three completed trials gave details of the randomization 
procedure, which was adequate in all cases, but only one, 
ie, AdAPT, described adequate allocation concealment. 
All three studies gave an explicit description of an adequate 
masking procedure for efficacy outcomes but an adequate 
masking procedure for adverse outcomes was only under-
taken in one study (AdAPT). In trials that included CBT, it 
was not possible to blind participants and clinicians to the 
delivery of CBT (AdAPT and TORdIA). In the TORdIA 
study, after 12 weeks of acute treatment, nonresponders were 
entered into indicated open-label treatment, which could 
consist of a higher medication dose, a switch to another 
medication, augmentation with another medication, CBT, 
or other psychotherapy. However, the independent evaluator 
remained blinded.
The attrition rate for the three completed trials   varied. 
It was relatively low in the AdAPT trial (6% in the 
fluoxetine-alone group and 10% in the fluoxetine + CBT 
group)   compared with the TORdIA study (27%–29% 
in the   medication-alone groups and 29%–30% in the 
medication + CBT groups). In the study by Birmaher et al, 
the attrition rate was 8% in the medication-only group 
compared with 36% in the   placebo group. Only one trial 
(TORdIA) reported on reasons for dropout in sufficient detail 
to be able to assess whether dropouts were because of side 
effects of treatment or to worsening depression, and in this 
trial the reasons were similar across all arms of the trial. In 
the Birmaher trial,46 there were more people withdrawn from 
the placebo group due to worsening depression than in the 
medication group. Both TORdIA and the medication-only 
trial appeared to include all randomized patients in an inten-
tion to treat analysis.
The investigators in the TORdIA study reported that their 
study was underpowered, and while baseline   characteristics 
were mostly similar across all treatment groups, the 
venlafaxine group had lower Beck depression Inventory 
scores and lower rates of post-traumatic stress disorder. 
There was also a change part way through this study from 
using paroxetine to citalopram, although this did not affect 
many participants. It should also be noted that the analysis 
of outcome data was not on the basis of the way participants 
were randomized (in a factorial design), but rather according 
to whether or not they received CBT.Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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p
t
o
m
s
 
(
i
n
c
l
u
d
i
n
g
 
o
n
e
 
c
o
r
e
 
m
o
o
d
 
s
y
m
p
t
o
m
 
o
f
 
s
a
d
n
e
s
s
,
 
i
r
r
i
t
a
b
i
l
i
t
y
,
 
o
r
 
a
n
h
e
d
o
n
i
a
)
 
d
u
r
i
n
g
 
2
-
w
e
e
k
 
p
e
r
i
o
d
 
 
a
n
d
 
p
r
e
s
e
n
t
 
o
n
 
a
s
s
e
s
s
m
e
n
t
 
p
l
u
s
 
H
o
N
O
S
C
A
 
 
s
c
o
r
e
 
$
7
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
s
c
h
i
z
o
p
h
r
e
n
i
a
 
o
r
 
b
i
p
o
l
a
r
 
d
i
s
o
r
d
e
r
;
 
n
e
e
d
 
f
o
r
 
i
m
m
e
d
i
a
t
e
 
i
n
p
a
t
i
e
n
t
 
a
d
m
i
s
s
i
o
n
;
 
p
r
e
v
i
o
u
s
 
o
p
t
i
m
a
l
 
t
r
e
a
t
m
e
n
t
 
w
i
t
h
 
b
o
t
h
 
S
S
R
i
 
a
n
d
 
C
B
T
 
w
i
t
h
 
n
o
 
e
f
f
e
c
t
2
0
8
M
e
a
n
:
 
1
4
 
y
e
a
r
s
 
 
(
S
D
 
1
.
5
)
 
 
F
e
m
a
l
e
:
 
 
7
4
%
T
o
t
a
l
 
m
e
d
i
a
n
 
(
r
a
n
g
e
)
 
i
n
d
e
x
 
e
p
i
s
o
d
e
:
 
 
4
0
 
w
e
e
k
s
 
(
3
–
6
2
4
)
 
F
l
u
o
x
e
t
i
n
e
:
 
5
2
 
(
4
–
6
2
4
)
 
fl
u
o
x
e
t
i
n
e
 
+
 
C
B
T
 
3
2
 
(
3
–
2
6
0
)
9
2
%
 
h
a
d
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
;
 
8
%
 
h
a
d
 
m
i
n
o
r
 
d
e
p
r
e
s
s
i
o
n
.
M
e
a
n
 
n
u
m
b
e
r
 
o
f
 
s
y
m
p
t
o
m
s
:
 
fl
u
o
x
e
t
i
n
e
 
+
 
C
B
T
 
6
.
6
 
(
S
D
 
1
.
5
)
;
 
fl
u
o
x
e
t
i
n
e
 
6
.
4
 
(
S
D
 
1
.
4
)
.
 
C
D
R
S
-
R
 
t
-
s
c
o
r
e
s
 
w
e
r
e
:
 
t
o
t
a
l
 
7
5
.
0
 
(
7
.
4
)
;
 
fl
u
o
x
e
t
i
n
e
 
7
5
.
3
 
(
6
.
7
)
;
 
fl
u
o
x
e
t
i
n
e
 
+
 
C
B
T
 
7
5
.
1
 
(
6
.
7
)
 
C
D
R
S
-
R
 
r
a
w
 
s
c
o
r
e
s
:
 
t
o
t
a
l
 
5
8
.
8
 
(
1
0
.
4
)
;
 
fl
u
o
x
e
t
i
n
e
 
5
9
.
0
 
(
9
.
5
)
;
 
fl
u
o
x
e
t
i
n
e
 
+
 
C
B
T
 
5
8
.
9
 
(
1
0
.
5
)
 
8
8
.
5
%
 
w
e
r
e
 
c
u
r
r
e
n
t
l
y
 
c
o
m
o
r
b
i
d
 
f
o
r
 
a
t
 
l
e
a
s
t
 
o
n
e
 
o
t
h
e
r
 
p
s
y
c
h
i
a
t
r
i
c
 
d
i
s
o
r
d
e
r
,
 
m
a
j
o
r
i
t
y
 
o
f
 
w
h
i
c
h
 
w
e
r
e
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
s
.
 
S
u
i
c
i
d
a
l
i
t
y
:
 
fl
u
o
x
e
t
i
n
e
,
 
i
d
e
a
t
i
o
n
 
4
2
.
7
%
,
 
a
t
t
e
m
p
t
s
 
2
0
.
4
%
;
 
fl
u
o
x
e
t
i
n
e
 
+
 
C
B
T
,
 
i
d
e
a
t
i
o
n
 
3
8
.
1
%
,
 
a
t
t
e
m
p
t
s
 
1
2
.
4
%
w
e
e
k
l
y
 
C
B
T
 
f
o
r
 
1
2
 
w
e
e
k
s
 
w
i
t
h
 
f
o
r
t
n
i
g
h
t
l
y
 
s
e
s
s
i
o
n
s
 
f
o
r
 
a
n
 
a
d
d
i
t
i
o
n
a
l
 
1
2
 
w
e
e
k
s
 
i
n
 
a
d
d
i
t
i
o
n
 
t
o
 
a
n
d
 
S
S
R
i
 
a
n
d
 
r
o
u
t
i
n
e
 
c
l
i
n
i
c
a
l
 
c
a
r
e
.
 
R
o
u
t
i
n
e
 
c
a
r
e
 
c
o
n
s
i
s
t
e
d
 
o
f
 
s
t
a
n
d
a
r
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
g
i
v
e
n
 
t
o
 
a
n
y
 
d
e
p
r
e
s
s
e
d
 
a
d
o
l
e
s
c
e
n
t
 
i
n
 
N
H
S
 
c
l
i
n
i
c
s
:
 
r
e
g
u
l
a
r
 
m
o
n
i
t
o
r
i
n
g
 
o
f
 
m
e
n
t
a
l
 
s
t
a
t
e
;
 
p
s
y
c
h
o
e
d
u
c
a
t
i
o
n
;
 
r
e
fl
e
c
t
i
o
n
,
 
s
u
p
p
o
r
t
 
a
n
d
 
e
n
c
o
u
r
a
g
e
m
e
n
t
 
t
o
 
a
d
o
l
e
s
c
e
n
t
s
 
a
n
d
 
t
h
e
i
r
 
f
a
m
i
l
i
e
s
;
 
 
p
r
o
b
l
e
m
 
s
o
l
v
i
n
g
;
 
a
t
t
e
n
t
i
o
n
 
t
o
 
 
c
o
-
m
o
r
b
i
d
i
t
y
;
 
a
n
d
 
l
i
a
i
s
o
n
 
w
i
t
h
 
o
t
h
e
r
 
p
r
o
f
e
s
s
i
o
n
a
l
s
,
 
s
u
c
h
 
a
s
 
t
e
a
c
h
e
r
s
 
a
n
d
 
s
o
c
i
a
l
 
w
o
r
k
e
r
s
S
S
R
i
 
(
p
r
i
m
a
r
i
l
y
 
fl
u
o
x
e
t
i
n
e
,
 
u
n
l
e
s
s
 
p
a
r
t
i
c
i
p
a
n
t
 
a
l
r
e
a
d
y
 
p
r
e
s
c
r
i
b
e
d
 
a
n
o
t
h
e
r
 
S
S
R
i
)
 
a
l
o
n
e
 
f
o
r
 
2
8
 
w
e
e
k
s
 
i
n
 
a
d
d
i
t
i
o
n
 
t
o
 
r
o
u
t
i
n
e
 
c
l
i
n
i
c
a
l
 
c
a
r
e
.
 
F
l
u
o
x
e
t
i
n
e
 
d
o
s
a
g
e
:
 
1
0
 
t
o
 
2
0
 
m
g
/
d
a
y
 
t
o
 
a
 
m
a
x
i
m
u
m
 
o
f
 
6
0
 
m
g
/
d
a
y
 
f
r
o
m
 
6
 
w
e
e
k
s
.
 
P
a
r
t
i
c
i
p
a
n
t
s
 
s
e
e
n
 
r
e
g
u
l
a
r
l
y
 
f
o
r
 
p
r
e
s
c
r
i
p
t
i
o
n
 
a
n
d
 
m
o
n
i
t
o
r
i
n
g
 
b
y
 
s
t
u
d
y
 
p
s
y
c
h
i
a
t
r
i
s
t
s
.
R
o
u
t
i
n
e
 
c
a
r
e
 
c
o
n
s
i
s
t
e
d
 
o
f
 
s
t
a
n
d
a
r
d
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
g
i
v
e
n
 
t
o
 
a
n
y
 
d
e
p
r
e
s
s
e
d
 
a
d
o
l
e
s
c
e
n
t
 
i
n
 
N
H
S
 
c
l
i
n
i
c
s
:
 
r
e
g
u
l
a
r
 
m
o
n
i
t
o
r
i
n
g
 
o
f
 
m
e
n
t
a
l
 
s
t
a
t
e
;
 
p
s
y
c
h
o
e
d
u
c
a
t
i
o
n
;
 
r
e
fl
e
c
t
i
o
n
,
 
s
u
p
p
o
r
t
 
a
n
d
 
e
n
c
o
u
r
a
g
e
m
e
n
t
 
t
o
 
a
d
o
l
e
s
c
e
n
t
s
 
a
n
d
 
t
h
e
i
r
 
f
a
m
i
l
i
e
s
;
 
p
r
o
b
l
e
m
 
s
o
l
v
i
n
g
;
 
a
t
t
e
n
t
i
o
n
 
t
o
 
c
o
-
m
o
r
b
i
d
i
t
y
;
 
a
n
d
 
l
i
a
i
s
o
n
 
w
i
t
h
 
o
t
h
e
r
 
p
r
o
f
e
s
s
i
o
n
a
l
s
,
 
s
u
c
h
 
a
s
 
t
e
a
c
h
e
r
s
 
a
n
d
 
s
o
c
i
a
l
 
w
o
r
k
e
r
s
2
8
 
w
e
e
k
s
 
(
f
r
o
m
 
b
a
s
e
l
i
n
e
)
B
i
r
m
a
h
e
r
4
6
M
a
y
v
i
e
w
 
S
t
a
t
e
 
H
o
s
p
i
t
a
l
 
i
n
p
a
t
i
e
n
t
s
i
n
p
a
t
i
e
n
t
s
R
e
f
e
r
r
e
d
 
f
o
r
 
l
o
n
g
-
t
e
r
m
 
h
o
s
p
i
t
a
l
i
z
a
t
i
o
n
 
d
u
e
 
t
o
 
f
a
i
l
i
n
g
 
t
o
 
r
e
s
p
o
n
d
 
t
o
i
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
A
g
e
:
 
1
2
–
1
8
 
D
i
a
g
n
o
s
i
s
:
 
n
o
n
p
s
y
c
h
o
t
i
c
 
m
a
j
o
r
2
7
M
e
a
n
:
 
1
6
.
2
 
 
(
S
D
 
1
.
4
)
 
F
e
m
a
l
e
:
 
7
0
%
T
o
t
a
l
 
m
e
a
n
 
i
n
d
e
x
 
e
p
i
s
o
d
e
 
6
1
.
2
 
w
e
e
k
s
 
(
S
D
 
3
1
.
4
)
 
m
e
d
i
M
e
a
n
 
H
D
R
S
 
w
a
s
 
 
2
2
.
4
 
(
S
D
 
7
.
3
)
 
 
6
 
p
a
r
t
i
c
i
p
a
n
t
s
A
m
i
t
r
i
p
t
y
l
i
n
e
 
f
o
r
 
1
0
 
w
e
e
k
s
 
D
o
s
a
g
e
:
 
d
a
i
l
y
P
l
a
c
e
b
o
 
f
o
r
 
1
0
 
w
e
e
k
s
N
o
n
e
 
r
e
p
o
r
t
e
d
s
e
v
e
r
a
l
 
p
s
y
c
h
o
s
o
c
i
a
l
 
a
n
d
/
o
r
 
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l
 
i
n
p
a
t
i
e
n
t
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
a
t
 
u
n
i
v
e
r
s
i
t
y
 
o
r
 
c
o
m
m
u
n
i
t
y
 
h
o
s
p
i
t
a
l
s
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
D
S
M
-
i
i
i
-
R
)
 
f
o
r
 
a
t
 
l
e
a
s
t
 
3
 
m
o
n
t
h
s
 
a
n
d
 
H
D
R
S
 
s
c
o
r
e
 
$
 
1
5
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
l
i
f
e
t
i
m
e
 
p
r
e
s
e
n
c
e
 
o
f
 
p
s
y
c
h
o
t
i
c
 
d
i
s
o
r
d
e
r
,
 
e
a
t
i
n
g
 
d
i
s
o
r
d
e
r
,
 
b
i
p
o
l
a
r
 
i
 
o
r
 
i
i
 
d
i
s
o
r
d
e
r
,
 
s
u
b
s
t
a
n
c
e
 
a
b
u
s
e
 
w
i
t
h
i
n
 
l
a
s
t
 
6
 
m
o
n
t
h
s
a
n
 
5
2
 
w
e
e
k
s
;
 
 
A
M
i
 
m
e
a
n
 
i
n
d
e
x
 
e
p
i
s
o
d
e
 
6
5
.
6
9
 
w
e
e
k
s
 
(
S
D
 
2
6
.
7
3
)
;
 
p
l
a
c
e
b
o
 
m
e
a
n
 
 
i
n
d
e
x
 
e
p
i
s
o
d
e
 
 
5
7
.
0
7
 
w
e
e
k
s
 
(
S
D
 
3
5
.
8
0
)
i
n
 
A
M
i
 
g
r
o
u
p
 
c
o
n
s
i
d
e
r
e
d
 
s
u
i
c
i
d
a
l
;
 
5
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
p
l
a
c
e
b
o
 
g
r
o
u
p
 
c
o
n
s
i
d
e
r
e
d
 
s
u
i
c
i
d
a
l
 
T
o
t
a
l
 
c
o
m
o
r
b
i
d
i
t
y
 
u
n
c
l
e
a
r
,
 
h
o
w
e
v
e
r
,
 
t
a
b
l
e
 
1
 
s
h
o
w
s
 
a
t
 
l
e
a
s
t
 
a
 
q
u
a
r
t
e
r
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
 
h
a
d
 
s
o
m
e
 
c
o
m
o
r
b
i
d
i
t
y
d
o
s
a
g
e
 
i
n
c
r
e
a
s
e
d
 
b
y
 
5
0
 
m
g
/
w
e
e
k
 
t
o
 
a
 
m
a
x
i
m
u
m
 
o
f
 
5
 
m
g
/
k
g
/
d
a
y
 
o
r
 
3
0
0
 
m
g
/
d
a
y
 
o
r
 
a
m
i
t
r
i
p
t
y
l
i
n
e
 
p
l
u
s
 
N
T
P
 
p
l
a
s
m
a
 
l
e
v
e
l
s
 
n
o
 
g
r
e
a
t
e
r
 
t
h
a
n
 
3
0
0
 
n
g
/
m
L
.
 
D
o
s
a
g
e
 
w
a
s
 
n
o
t
 
i
n
c
r
e
a
s
e
d
 
i
f
 
p
a
t
i
e
n
t
 
s
h
o
w
e
d
 
i
m
p
r
o
v
e
m
e
n
t
.
 
D
u
r
i
n
g
 
t
h
e
 
p
r
o
t
o
c
o
l
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
a
l
l
o
w
e
d
 
t
o
 
t
a
k
e
 
l
o
r
a
z
e
p
a
m
 
f
o
r
 
s
e
v
e
r
e
 
a
g
i
t
a
t
i
o
n
 
o
r
 
i
n
s
o
m
n
i
a
.
 
T
h
e
y
 
a
l
s
o
 
p
a
r
t
i
c
i
p
a
t
e
d
 
i
n
 
p
s
y
c
h
o
s
o
c
i
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
(
e
g
,
 
g
r
o
u
p
s
,
 
p
l
a
c
e
m
e
n
t
 
p
r
e
p
a
r
a
t
i
o
n
)
.
R
o
b
i
n
s
4
5
P
r
i
m
a
r
y
 
c
a
r
e
P
s
y
c
h
i
a
t
r
i
c
 
 
o
u
t
p
a
t
i
e
n
t
s
N
o
n
r
e
s
p
o
n
d
e
r
s
 
t
o
 
8
 
w
e
e
k
s
 
o
f
 
fl
u
o
x
e
t
i
n
e
,
 
o
n
 
a
t
 
l
e
a
s
t
 
4
0
 
m
g
/
d
a
y
i
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
a
g
e
 
1
3
–
1
7
 
y
e
a
r
s
;
 
d
i
a
g
n
o
s
i
s
 
o
f
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
v
e
 
e
p
i
s
o
d
e
 
(
D
S
M
-
i
v
 
c
r
i
t
e
r
i
a
)
 
f
r
o
m
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
 
o
r
 
b
i
p
o
l
a
r
 
d
i
s
o
r
d
e
r
.
 
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
s
u
i
c
i
d
e
 
r
i
s
k
 
d
e
fi
n
e
d
 
a
s
 
m
e
d
i
c
a
l
l
y
N
A
N
A
N
A
N
A
F
l
u
o
x
e
t
i
n
e
 
a
u
g
m
e
n
t
e
d
 
b
y
 
l
a
m
o
t
r
i
g
i
n
e
 
f
o
r
 
8
 
w
e
e
k
s
S
e
r
t
r
a
l
i
n
e
 
f
o
r
 
8
 
w
e
e
k
s
N
A
T
O
R
D
I
A
4
8
C
l
i
n
i
c
a
l
 
s
o
u
r
c
e
s
 
(
7
9
.
9
%
)
 
a
n
d
 
a
d
v
e
r
t
i
s
e
-
m
e
n
t
s
 
(
2
0
.
1
%
)
M
u
l
t
i
p
l
e
-
s
i
t
e
 
s
t
u
d
y
 
i
n
 
o
u
t
p
a
t
i
e
n
t
 
c
l
i
n
i
c
s
F
a
i
l
u
r
e
 
t
o
 
r
e
s
p
o
n
d
 
t
o
 
 
S
S
R
i
 
t
r
e
a
t
m
e
n
t
 
r
e
g
i
m
e
n
 
o
f
 
a
t
 
l
e
a
s
t
 
8
 
w
e
e
k
s
,
 
t
h
e
 
l
a
s
t
 
4
 
o
f
 
w
h
i
c
h
 
w
e
r
e
 
a
t
 
a
 
d
o
s
a
g
e
 
o
f
 
a
t
 
l
e
a
s
t
 
4
0
 
m
g
/
d
a
y
 
fl
u
o
x
e
t
i
n
e
 
(
o
r
 
e
q
u
i
v
a
l
e
n
t
)
.
 
i
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
 
a
g
e
 
1
2
–
1
8
 
y
e
a
r
s
;
 
 
d
i
a
g
n
o
s
i
s
:
 
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
D
S
M
-
i
v
)
 
p
l
u
s
 
C
D
R
S
-
R
 
s
c
o
r
e
 
$
 
4
0
 
a
n
d
 
C
G
i
-
S
 
s
c
o
r
e
 
$
 
4
.
 
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
3
3
4
M
e
a
n
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D
 
1
.
4
)
 
F
e
m
a
l
e
:
 
7
0
%
T
o
t
a
l
 
m
e
a
n
 
i
n
d
e
x
 
e
p
i
s
o
d
e
 
6
1
.
2
 
w
e
e
k
s
 
(
S
D
 
3
1
.
4
)
 
m
e
d
i
M
e
a
n
 
H
D
R
S
 
w
a
s
 
 
2
2
.
4
 
(
S
D
 
7
.
3
)
 
 
6
 
p
a
r
t
i
c
i
p
a
n
t
s
A
m
i
t
r
i
p
t
y
l
i
n
e
 
f
o
r
 
1
0
 
w
e
e
k
s
 
D
o
s
a
g
e
:
 
d
a
i
l
y
P
l
a
c
e
b
o
 
f
o
r
 
1
0
 
w
e
e
k
s
N
o
n
e
 
r
e
p
o
r
t
e
d
s
e
v
e
r
a
l
 
p
s
y
c
h
o
s
o
c
i
a
l
 
a
n
d
/
o
r
 
p
h
a
r
m
a
c
o
l
o
g
i
c
a
l
 
i
n
p
a
t
i
e
n
t
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
a
t
 
u
n
i
v
e
r
s
i
t
y
 
o
r
 
c
o
m
m
u
n
i
t
y
 
h
o
s
p
i
t
a
l
s
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
D
S
M
-
i
i
i
-
R
)
 
f
o
r
 
a
t
 
l
e
a
s
t
 
3
 
m
o
n
t
h
s
 
a
n
d
 
H
D
R
S
 
s
c
o
r
e
 
$
 
1
5
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
l
i
f
e
t
i
m
e
 
p
r
e
s
e
n
c
e
 
o
f
 
p
s
y
c
h
o
t
i
c
 
d
i
s
o
r
d
e
r
,
 
e
a
t
i
n
g
 
d
i
s
o
r
d
e
r
,
 
b
i
p
o
l
a
r
 
i
 
o
r
 
i
i
 
d
i
s
o
r
d
e
r
,
 
s
u
b
s
t
a
n
c
e
 
a
b
u
s
e
 
w
i
t
h
i
n
 
l
a
s
t
 
6
 
m
o
n
t
h
s
a
n
 
5
2
 
w
e
e
k
s
;
 
 
A
M
i
 
m
e
a
n
 
i
n
d
e
x
 
e
p
i
s
o
d
e
 
6
5
.
6
9
 
w
e
e
k
s
 
(
S
D
 
2
6
.
7
3
)
;
 
p
l
a
c
e
b
o
 
m
e
a
n
 
 
i
n
d
e
x
 
e
p
i
s
o
d
e
 
 
5
7
.
0
7
 
w
e
e
k
s
 
(
S
D
 
3
5
.
8
0
)
i
n
 
A
M
i
 
g
r
o
u
p
 
c
o
n
s
i
d
e
r
e
d
 
s
u
i
c
i
d
a
l
;
 
5
 
p
a
r
t
i
c
i
p
a
n
t
s
 
i
n
 
p
l
a
c
e
b
o
 
g
r
o
u
p
 
c
o
n
s
i
d
e
r
e
d
 
s
u
i
c
i
d
a
l
 
T
o
t
a
l
 
c
o
m
o
r
b
i
d
i
t
y
 
u
n
c
l
e
a
r
,
 
h
o
w
e
v
e
r
,
 
t
a
b
l
e
 
1
 
s
h
o
w
s
 
a
t
 
l
e
a
s
t
 
a
 
q
u
a
r
t
e
r
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
 
h
a
d
 
s
o
m
e
 
c
o
m
o
r
b
i
d
i
t
y
d
o
s
a
g
e
 
i
n
c
r
e
a
s
e
d
 
b
y
 
5
0
 
m
g
/
w
e
e
k
 
t
o
 
a
 
m
a
x
i
m
u
m
 
o
f
 
5
 
m
g
/
k
g
/
d
a
y
 
o
r
 
3
0
0
 
m
g
/
d
a
y
 
o
r
 
a
m
i
t
r
i
p
t
y
l
i
n
e
 
p
l
u
s
 
N
T
P
 
p
l
a
s
m
a
 
l
e
v
e
l
s
 
n
o
 
g
r
e
a
t
e
r
 
t
h
a
n
 
3
0
0
 
n
g
/
m
L
.
 
D
o
s
a
g
e
 
w
a
s
 
n
o
t
 
i
n
c
r
e
a
s
e
d
 
i
f
 
p
a
t
i
e
n
t
 
s
h
o
w
e
d
 
i
m
p
r
o
v
e
m
e
n
t
.
 
D
u
r
i
n
g
 
t
h
e
 
p
r
o
t
o
c
o
l
 
p
a
t
i
e
n
t
s
 
w
e
r
e
 
a
l
l
o
w
e
d
 
t
o
 
t
a
k
e
 
l
o
r
a
z
e
p
a
m
 
f
o
r
 
s
e
v
e
r
e
 
a
g
i
t
a
t
i
o
n
 
o
r
 
i
n
s
o
m
n
i
a
.
 
T
h
e
y
 
a
l
s
o
 
p
a
r
t
i
c
i
p
a
t
e
d
 
i
n
 
p
s
y
c
h
o
s
o
c
i
a
l
 
i
n
t
e
r
v
e
n
t
i
o
n
s
 
(
e
g
,
 
g
r
o
u
p
s
,
 
p
l
a
c
e
m
e
n
t
 
p
r
e
p
a
r
a
t
i
o
n
)
.
R
o
b
i
n
s
4
5
P
r
i
m
a
r
y
 
c
a
r
e
P
s
y
c
h
i
a
t
r
i
c
 
 
o
u
t
p
a
t
i
e
n
t
s
N
o
n
r
e
s
p
o
n
d
e
r
s
 
t
o
 
8
 
w
e
e
k
s
 
o
f
 
fl
u
o
x
e
t
i
n
e
,
 
o
n
 
a
t
 
l
e
a
s
t
 
4
0
 
m
g
/
d
a
y
i
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
a
g
e
 
1
3
–
1
7
 
y
e
a
r
s
;
 
d
i
a
g
n
o
s
i
s
 
o
f
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
v
e
 
e
p
i
s
o
d
e
 
(
D
S
M
-
i
v
 
c
r
i
t
e
r
i
a
)
 
f
r
o
m
 
m
a
j
o
r
 
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
 
o
r
 
b
i
p
o
l
a
r
 
d
i
s
o
r
d
e
r
.
 
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
s
u
i
c
i
d
e
 
r
i
s
k
 
d
e
fi
n
e
d
 
a
s
 
m
e
d
i
c
a
l
l
y
N
A
N
A
N
A
N
A
F
l
u
o
x
e
t
i
n
e
 
a
u
g
m
e
n
t
e
d
 
b
y
 
l
a
m
o
t
r
i
g
i
n
e
 
f
o
r
 
8
 
w
e
e
k
s
S
e
r
t
r
a
l
i
n
e
 
f
o
r
 
8
 
w
e
e
k
s
N
A
T
O
R
D
I
A
4
8
C
l
i
n
i
c
a
l
 
s
o
u
r
c
e
s
 
(
7
9
.
9
%
)
 
a
n
d
 
a
d
v
e
r
t
i
s
e
-
m
e
n
t
s
 
(
2
0
.
1
%
)
M
u
l
t
i
p
l
e
-
s
i
t
e
 
s
t
u
d
y
 
i
n
 
o
u
t
p
a
t
i
e
n
t
 
c
l
i
n
i
c
s
F
a
i
l
u
r
e
 
t
o
 
r
e
s
p
o
n
d
 
t
o
 
 
S
S
R
i
 
t
r
e
a
t
m
e
n
t
 
r
e
g
i
m
e
n
 
o
f
 
a
t
 
l
e
a
s
t
 
8
 
w
e
e
k
s
,
 
t
h
e
 
l
a
s
t
 
4
 
o
f
 
w
h
i
c
h
 
w
e
r
e
 
a
t
 
a
 
d
o
s
a
g
e
 
o
f
 
a
t
 
l
e
a
s
t
 
4
0
 
m
g
/
d
a
y
 
fl
u
o
x
e
t
i
n
e
 
(
o
r
 
e
q
u
i
v
a
l
e
n
t
)
.
 
i
n
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
 
a
g
e
 
1
2
–
1
8
 
y
e
a
r
s
;
 
 
d
i
a
g
n
o
s
i
s
:
 
d
e
p
r
e
s
s
i
v
e
 
d
i
s
o
r
d
e
r
 
(
D
S
M
-
i
v
)
 
p
l
u
s
 
C
D
R
S
-
R
 
s
c
o
r
e
 
$
 
4
0
 
a
n
d
 
C
G
i
-
S
 
s
c
o
r
e
 
$
 
4
.
 
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
:
 
3
3
4
M
e
a
n
 
1
6
 
y
e
a
r
s
,
 
f
e
m
a
l
e
 
7
0
%
T
o
t
a
l
 
d
u
r
a
t
i
o
n
 
o
f
 
c
u
r
r
e
n
t
 
e
p
i
s
o
d
e
 
(
m
e
d
i
a
n
 
1
7
 
m
o
n
t
h
s
 
S
S
R
i
 
g
r
o
u
p
s
 
(
m
e
a
n
)
:
 
 
2
3
.
5
 
(
S
D
 
2
1
.
6
)
 
v
e
n
l
a
f
a
x
i
n
e
 
g
r
o
u
p
s
 
(
m
e
a
n
)
:
 
2
1
.
4
 
(
S
D
 
1
9
.
0
)
 
T
o
t
a
l
:
 
m
o
d
e
r
a
t
e
l
y
 
 
s
e
v
e
r
e
 
d
e
p
r
e
s
s
i
o
n
 
 
C
D
R
S
-
R
 
=
 
5
9
 
 
S
S
R
i
 
g
r
o
u
p
s
 
 
(
m
e
a
n
 
C
D
R
S
-
R
)
:
S
S
R
i
 
a
l
o
n
e
 
o
r
 
v
e
n
l
a
f
a
x
i
n
e
 
a
l
o
n
e
 
f
o
r
 
1
2
 
w
e
e
k
s
.
 
D
o
s
a
g
e
:
 
F
o
r
 
S
S
R
i
 
1
0
 
m
g
/
d
a
y
 
f
o
r
 
w
e
e
k
 
1
 
a
n
d
 
2
0
 
m
g
/
d
a
y
 
f
o
r
 
w
e
e
k
s
 
2
 
t
o
 
6
 
w
i
t
h
 
o
p
t
i
o
n
 
t
o
 
i
n
c
r
e
a
s
e
 
t
o
A
d
d
i
t
i
o
n
 
o
f
 
C
B
T
 
t
o
 
S
S
R
i
 
o
r
 
v
e
n
l
a
f
a
x
i
n
e
.
 
C
B
T
 
i
n
c
l
u
d
e
d
 
1
2
 
w
e
e
k
l
y
 
s
e
s
s
i
o
n
s
 
o
f
 
C
B
T
 
o
f
 
6
0
 
t
o
 
9
0
 
m
i
n
u
t
e
 
d
u
r
a
t
i
o
n
,
 
3
 
t
o
 
6
 
o
f
 
w
h
i
c
h
 
w
e
r
e
 
t
o
 
b
e
 
f
a
m
i
l
y
 
s
e
s
s
i
o
n
s
.
2
4
 
w
e
e
k
s
(
C
o
n
t
i
n
u
e
d
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T
a
b
l
e
 
1
 
(
C
o
n
t
i
n
u
e
d
)
S
t
u
d
y
S
e
t
t
i
n
g
 
f
o
r
 
r
e
c
r
u
i
t
m
e
n
t
S
e
t
t
i
n
g
 
f
o
r
 
i
n
t
e
r
v
e
n
t
i
o
n
D
e
fi
n
i
t
i
o
n
 
t
r
e
a
t
m
e
n
t
 
r
e
s
i
s
t
a
n
c
e
I
n
c
l
u
s
i
o
n
 
a
n
d
 
e
x
c
l
u
s
i
o
n
 
c
r
i
t
e
r
i
a
 
 
(
p
s
y
c
h
i
a
t
r
i
c
 
d
i
s
o
r
d
e
r
s
)
n
A
g
e
/
G
e
n
d
e
r
D
u
r
a
t
i
o
n
 
o
f
 
i
l
l
n
e
s
s
/
D
u
r
a
t
i
o
n
 
 
o
f
 
t
h
i
s
 
e
p
i
s
o
d
e
 
 
(
i
n
 
e
a
c
h
 
g
r
o
u
p
)
C
o
m
o
r
b
i
d
i
t
y
/
 
 
S
e
v
e
r
i
t
y
 
o
f
 
 
i
l
l
n
e
s
s
/
S
u
i
c
i
d
e
 
 
r
i
s
k
I
n
t
e
r
v
e
n
t
i
o
n
/
L
e
n
g
t
h
C
o
m
p
a
r
i
s
o
n
F
o
l
l
o
w
-
u
p
T
O
R
D
I
A
 
c
o
n
t
.
A
l
s
o
 
i
n
c
l
u
d
e
d
 
p
a
r
t
i
c
i
p
a
n
t
s
,
 
 
w
h
o
 
a
f
t
e
r
 
a
t
t
e
m
p
t
i
n
g
 
a
 
d
o
s
a
g
e
 
c
o
m
p
a
r
a
b
l
e
 
t
o
 
4
0
 
m
g
/
d
a
y
 
fl
u
o
x
e
t
i
n
e
 
c
o
u
l
d
 
o
n
l
y
 
t
o
l
e
r
a
t
e
 
a
 
d
o
s
e
 
t
h
a
t
 
w
a
s
 
e
q
u
i
v
a
l
e
n
t
 
t
o
 
2
0
 
m
g
/
d
a
y
 
fl
u
o
x
e
t
i
n
e
 
f
o
r
 
a
t
 
l
e
a
s
t
 
4
 
w
e
e
k
s
 
(
1
9
/
3
3
4
)
.
 
N
o
t
e
 
e
x
c
l
u
s
i
o
n
 
o
f
 
p
a
r
t
i
c
i
p
a
n
t
s
 
w
i
t
h
 
$
 
2
 
f
a
i
l
e
d
 
t
r
i
a
l
s
 
o
f
 
S
S
R
i
s
 
o
r
 
h
i
s
t
o
r
y
 
o
f
 
n
o
n
r
e
s
p
o
n
s
e
 
t
o
 
v
e
n
l
a
f
a
x
i
n
e
 
o
r
 
t
o
 
C
B
T
 
(
$
 
7
 
s
e
s
s
i
o
n
s
)
b
i
p
o
l
a
r
 
s
p
e
c
t
r
u
m
 
d
i
s
o
r
d
e
r
s
;
 
p
s
y
c
h
o
s
e
s
;
 
p
e
r
v
a
s
i
v
e
 
d
e
v
e
l
o
p
m
e
n
t
a
l
 
d
i
s
o
r
d
e
r
s
 
o
r
 
a
u
t
i
s
m
;
 
e
a
t
i
n
g
 
d
i
s
o
r
d
e
r
s
;
 
s
u
b
s
t
a
n
c
e
 
a
b
u
s
e
 
o
f
 
d
e
p
e
n
d
e
n
c
e
 
C
B
T
 
g
r
o
u
p
s
 
(
m
e
a
n
)
:
 
2
2
.
6
 
(
S
D
 
2
1
.
4
)
 
N
o
n
-
C
B
T
 
g
r
o
u
p
s
 
(
m
e
a
n
)
:
 
2
2
.
3
 
(
S
D
 
1
9
.
4
)
5
9
.
9
 
(
S
D
 
1
0
.
6
)
 
v
e
n
l
a
f
a
x
i
n
e
 
g
r
o
u
p
s
 
(
m
e
a
n
 
C
D
R
S
-
R
)
:
 
5
7
.
8
 
(
S
D
 
1
0
.
1
)
 
C
B
T
 
g
r
o
u
p
s
 
 
(
m
e
a
n
 
C
D
R
S
-
R
)
:
 
5
8
.
4
 
(
S
D
 
9
.
7
)
 
N
o
n
-
C
B
T
 
g
r
o
u
p
s
 
(
m
e
a
n
 
C
D
R
S
-
R
)
:
 
5
9
.
2
 
(
S
D
 
1
1
.
0
)
 
7
2
.
1
%
 
fi
r
s
t
 
e
p
i
s
o
d
e
 
5
8
.
5
%
 
c
l
i
n
i
c
a
l
l
y
 
s
i
g
n
i
fi
c
a
n
t
 
s
u
i
c
i
d
a
l
 
i
d
e
a
t
i
o
n
 
5
1
.
5
%
 
h
a
d
 
a
t
 
l
e
a
s
t
 
o
n
e
 
c
o
m
o
r
b
i
d
 
d
i
s
o
r
d
e
r
,
 
t
h
e
 
m
a
j
o
r
i
t
y
 
o
f
 
w
h
i
c
h
 
w
e
r
e
 
a
n
x
i
e
t
y
 
d
i
s
o
r
d
e
r
s
 
o
r
 
d
y
s
t
h
y
m
i
a
m
a
x
i
m
u
m
 
o
f
 
6
0
 
m
g
/
d
a
y
 
t
h
e
r
e
a
f
t
e
r
.
 
F
o
r
 
v
e
n
l
a
f
a
x
i
n
e
 
d
o
s
a
g
e
s
 
f
o
r
 
w
e
e
k
s
 
1
 
t
o
 
4
 
w
e
r
e
 
7
.
5
,
 
7
5
,
 
1
1
2
.
5
,
 
a
n
d
 
1
5
0
 
m
g
 
w
i
t
h
 
o
p
t
i
o
n
 
t
o
 
i
n
c
r
e
a
s
e
 
t
o
 
2
2
5
 
m
g
 
a
t
 
w
e
e
k
 
6
.
 
P
h
a
r
m
a
c
o
t
h
e
r
a
p
y
 
s
e
s
s
i
o
n
s
 
w
e
r
e
 
b
e
t
w
e
e
n
 
3
0
 
a
n
d
 
6
0
 
m
i
n
u
t
e
s
;
 
c
o
n
d
u
c
t
e
d
 
b
y
 
p
s
y
c
h
i
a
t
r
i
s
t
s
 
o
r
 
m
a
s
t
e
r
’
s
 
d
e
g
r
e
e
 
l
e
v
e
l
 
n
u
r
s
e
s
 
s
u
p
e
r
v
i
s
e
d
 
b
y
 
p
s
y
c
h
i
a
t
r
i
s
t
;
 
c
o
n
s
i
s
t
e
d
 
o
f
 
s
a
f
e
t
y
 
a
s
s
e
s
s
m
e
n
t
 
a
n
d
 
o
c
c
u
r
r
e
d
 
w
e
e
k
l
y
 
f
o
r
 
4
 
w
e
e
k
s
 
a
n
d
 
b
i
w
e
e
k
l
y
 
t
h
e
r
e
a
f
t
e
r
.
 
 
A
l
l
 
p
a
r
t
i
c
i
p
a
n
t
s
 
r
e
c
e
i
v
e
d
 
f
a
m
i
l
y
 
p
s
y
c
h
o
e
d
u
c
a
t
i
o
n
 
a
t
 
i
n
t
a
k
e
,
 
6
-
w
e
e
k
 
m
i
d
p
o
i
n
t
 
a
n
d
 
1
2
-
w
e
e
k
 
e
n
d
 
o
f
 
a
c
u
t
e
 
t
r
e
a
t
m
e
n
t
T
h
e
r
a
p
i
s
t
s
 
w
e
r
e
 
a
t
 
l
e
a
s
t
 
m
a
s
t
e
r
’
s
 
l
e
v
e
l
 
w
i
t
h
 
e
x
p
e
r
i
e
n
c
e
 
i
n
 
C
B
T
.
 
 
C
B
T
 
d
r
e
w
 
o
n
 
m
a
n
u
a
l
s
 
t
h
a
t
 
e
m
p
h
a
s
i
z
e
 
c
o
g
n
i
t
i
v
e
 
r
e
s
t
r
u
c
t
u
r
i
n
g
 
a
n
d
 
b
e
h
a
v
i
o
r
a
l
 
a
c
t
i
v
a
t
i
o
n
,
 
e
m
o
t
i
o
n
 
r
e
g
u
l
a
t
i
o
n
,
 
s
o
c
i
a
l
 
s
k
i
l
l
s
 
a
n
d
 
p
r
o
b
l
e
m
 
s
o
l
v
i
n
g
;
 
a
n
d
 
t
h
a
t
 
a
l
s
o
 
e
m
p
h
a
s
i
z
e
 
p
a
r
e
n
t
-
c
h
i
l
d
 
s
e
s
s
i
o
n
s
 
t
o
 
d
e
c
r
e
a
s
e
 
c
r
i
t
i
c
i
s
m
 
a
n
d
 
i
m
p
r
o
v
e
 
s
u
p
p
o
r
t
,
 
f
a
m
i
l
y
 
c
o
m
m
u
n
i
c
a
t
i
o
n
 
a
n
d
 
p
r
o
b
l
e
m
 
s
o
l
v
i
n
g
.
 
M
o
d
u
l
e
s
 
w
e
r
e
 
fl
e
x
i
b
l
y
 
a
p
p
l
i
e
d
 
d
e
p
e
n
d
i
n
g
 
o
n
 
c
l
i
n
i
c
a
l
 
n
e
e
d
A
b
b
r
e
v
i
a
t
i
o
n
s
:
 
C
B
T
,
 
c
o
g
n
i
t
i
v
e
 
b
e
h
a
v
i
o
r
a
l
 
t
h
e
r
a
p
y
;
 
S
S
R
i
s
,
 
s
e
l
e
c
t
i
v
e
 
s
e
r
o
t
o
n
i
n
 
r
e
u
p
t
a
k
e
 
i
n
h
i
b
i
t
o
r
s
;
 
S
D
,
 
s
t
a
n
d
a
r
d
 
d
e
v
i
a
t
i
o
n
;
 
C
G
i
,
 
C
l
i
n
i
c
a
l
 
G
l
o
b
a
l
 
i
m
p
r
e
s
s
i
o
n
;
 
C
D
R
S
-
R
,
 
C
h
i
l
d
r
e
n
’
s
 
D
e
p
r
e
s
s
i
o
n
 
R
a
t
i
n
g
 
S
c
a
l
e
-
R
e
v
i
s
e
d
;
 
H
o
N
O
S
C
A
,
 
H
e
a
l
t
h
 
o
f
 
t
h
e
 
N
a
t
i
o
n
 
O
u
t
c
o
m
e
 
S
c
a
l
e
s
 
f
o
r
 
C
h
i
l
d
r
e
n
 
a
n
d
 
A
d
o
l
e
s
c
e
n
t
s
;
 
D
S
M
,
 
D
i
a
g
n
o
s
t
i
c
 
a
n
d
 
S
t
a
t
i
s
t
i
c
a
l
 
M
a
n
u
a
l
 
o
f
 
M
e
n
t
a
l
 
D
i
s
o
r
d
e
r
s
;
 
C
A
M
H
S
,
 
C
h
i
l
d
 
a
n
d
 
A
d
o
l
e
s
c
e
n
t
 
M
e
n
t
a
l
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
;
 
N
H
S
,
 
N
a
t
i
o
n
a
l
 
H
e
a
l
t
h
 
S
e
r
v
i
c
e
.Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
105
CBT for treatment-resistant adolescent depression
In AdAPT, the study psychiatrists delivered both arms of 
the intervention, raising the possibility of cross   contamination. 
Routine treatment in both groups included some elements of 
CBT. There were also additional interventions received as part 
of routine care, the details of which were not recorded. none 
of the three completed studies had pharmaceutical funding. 
details of the included studies are included in Table 2.
effects of medical interventions
Medication versus placebo
One trial examined the effects of a medication (amitriptyline, 
a tricyclic antidepressant) compared with a placebo for 
participants who had not responded to previous interven-
tions, which included tricyclic antidepressants, sertraline, 
paroxetine or fluvoxamine, and lithium. data for this trial 
are presented in Table 3.
Response
The trial authors reported that there was no difference 
between groups in response, with similar numbers no longer 
fulfilling criteria for major depressive disorder at the end of 
the study. At the end of the treatment period, 30% continued 
to fulfill criteria for major depressive disorder and about 60% 
continued to have subsyndromal symptoms. The trial authors 
report that only an initial self-rated depression score on the 
Beck depression Inventory (BdI) predicted response. The 
investigators also reported that the medication and placebo 
groups demonstrated similar decreases in the HdRS, and 
that the two groups had similar decreases in self-rated BdI 
scores, with no significant difference between the medication 
and placebo groups.
Addition of CBT
There were two studies that tested the effectiveness of adding 
CBT to a medication regimen and some data from these trials 
could be combined in meta-analysis. It should be noted that 
the data for the TORdIA study were not presented by the 
group to which participants were originally assigned, rather 
results were presented according to whether participants 
received CBT or not. In the group receiving medication 
only, approximately half received an SSRI and half received 
venlafaxine.
Response
For response, we used the definition of a CGI score # 2 
(much or very much improved). Based on this definition, 
the response rates were 43.5% in the AdAPT study and 
47.6% in the TORdIA study in the groups who received no 
additional CBT and 42% in the AdAPT study and 59% in 
the TORdIA study in those groups who did receive CBT 
(see Table 3). This equated to a 2% risk difference between 
the group who received CBT and the group who did not in 
the AdAPT study, and an 11% risk difference between the 
group who received CBT and the group who did not in the 
TORdIA study. This difference was not significant when data 
from both studies were combined (relative risk 0.89, 95% 
CI 0.69–1.15, see Figure 2). The AdAPT study included a 
28-week follow-up and showed no significant differences 
between the groups.
Our definition of response was the same as that used in 
the AdAPT study, and our results are consistent with their 
reporting. However, the TORdIA study authors defined 
response as a CGI score , 2 and 50% improvement in 
CdRS-R scores, and found a significantly higher rate of 
response in the group who received CBT (54.8%) compared 
with those who did not (40.5%).48 The authors reported that 
depression severity at baseline was the strongest predictor 
of nonresponse.50
In the AdAPT study, the primary outcome variable 
was Health of the nation Outcome Scales for Children and 
  Adolescents (HonOSCA). Using this scale, the authors 
reported nearly identical response rates, with 96% of young 
people who received CBT and 98% of those who did not 
receive CBT responding over 12 weeks. In the longer report 
of the AdAPT study,51 the authors defined response as a CGI 
score # 3. Based on this definition, they report that 80% 
of the participants responded by 28 weeks of follow-up, 
and estimated that only about 10% of the trial participants 
were nonresponders, labeling this group “truly treatment-
resistant.” They did not report an analysis of predictors 
of nonresponse. In a meta-analysis of response data using 
the TORdIA study definition and the AdAPT HonOSCA 
definition of response, there was no differences between those 
who received CBT and those who did not (relative risk 0.86, 
95% CI 0.39–1.92).
Clinician-rated depression symptoms
There were no significant differences between groups in 
clinician-rated depression severity using the CdRS-R (mean 
difference 0.30, 95% CI −3.85 to 3.26) post intervention 
(see Figure 3). The AdAPT trial reported 28-week follow-up, 
and there continued to be no significant differences between 
the groups. The results of the meta-analysis are consistent 
with the way the results were reported by the individual 
studies included in the meta-analysis with regard to clinician-
reported severity of depression.Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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Table 2 Risk of bias
Study Randomization 
procedure
Allocation 
concealment
Blinding of outcome  
assessor (efficacy  
outcomes)
Blinding of outcome 
assessor (adverse 
outcomes)
Blinding of 
participants/ 
care givers
Withdrawals n (%) 
in each group
Withdrawals due to 
treatment in each 
group
Intention to treat analysis Other Funding
ADAPT47 Adequate: 
Stochastic 
minimization was 
used to ensure 
balance on 
severity, center, 
sex, comorbid 
behavioral disorder 
(probable or definite 
oppositional defiant 
disorder or conduct 
disorder) and 
age. Page 15 HTA 
report51
Adequate:  
The study psychiatrist 
telephoned an 
independent centre, 
the Department of 
Medical Statistics at 
the Christie Hospital 
in Manchester, for 
randomization.  
Page 15 HTA 
report51
Adequate:  
Outcome assessments were done 
by independent evaluators blind 
to treatment assignment. Specific 
instructions were given to participants, 
parents, and treating clinicians not to 
disclose treatment assignment to the 
blinded evaluator. Page 15 HTA report51
Adequate:  
Adverse events were 
recorded at each 
assessment interview 
(which were conducted 
by blind outcome 
assessors). Page 10 HTA 
report51
Inadequate:  
Study compared 
CBT with non-
CBT, therefore 
participants and 
study clinicians could 
not be blind to 
treatment
Adequate:  
Fluoxetine alone  
week 12: 6/103 (6%) 
week 28: 13/103 
(13%)  
 
Fluoxetine + CBT  
week 12: 11/105 
(10%)  
week 28: 18/105 
(17%)
Unclear:  
Not enough detail 
provided about reasons 
for drop out by group
Inadequate:  
included in primary endpoint 
analysis: Fluoxetine 101/103 
Fluoxetine + CBT 102/105
Unclear:
1. Study psychiatrists delivered 
intervention in both arms so cross 
contamination is possible 
2. Routine care stated to include 
principles of CBT treatment were 
part of routine clinical care; however, 
care mainly took the form of advice, 
rather than collaborative goal setting, 
homework, rewards, and exploration 
and challenging of negative cognitions. 
Sessions were shorter and fewer
3. Precise details of any additional 
routinely offered CAMHS services 
were not systematically assessed
Adequate: 
There was no 
commercial 
sponsorship. 
Page 51 HTA 
report
Birmaher46  Adequate:  
“[R]andomly 
assigned using a 
modification of 
efon’s biased coin 
toss to match 
approximately for 
age and gender.” 
Page 528
Unclear:  
No detail
Adequate:  
Psychiatric research nurse administered 
outcome measurement. “To maintain 
blindness of treatment assignment, the 
research nurse was unaware of the 
results of the side effect evaluations.” 
Page 529
Inadequate:  
The only nonblind 
investigator monitored 
patients’ responses to 
treatment, AMi doses, 
and presence of side 
effects. This investigator 
was not involved in any 
of the ratings of the 
patient.” Page 529
Adequate:  
“After randomization, 
patients received 
identical tablets of 
placebo or AMi. To 
ensure blindness to 
treatment allocation, 
each patient received 
three pills twice a 
day.” Page 528
Adequate:  
AMi: 1/13 (8%) 
Placebo: 5/14 (36% )
Inadequate:  
withdrawn from study 
due to worsening of 
clinical symptoms: AMi: 
1 Placebo: 5 Page 530
Adequate:  
Stated to be done on page 529  
and table 2 includes all participants 
randomized. Note authors also 
undertook completer analysis, 
analysis of patients who completed 
at least 4 weeks of treatment, and 
stated there was no difference 
in outcome. Page 529
Unclear:  
1. Small study 
2. Previous treatment ascertained 
from medical records, raising the 
possibility of incomplete or inaccurate 
information, meaning the population 
may not truly be treatment resistant
Adequate: 
NiMH grant
Robins45 Unclear:  
No detail
Unclear:  
No detail
Unclear:  
States blinding will be maintained by the 
comparison group receiving a placebo 
augmentation
Unclear:  
States blinding will 
be maintained by the 
comparison group 
receiving a placebo 
augmentation
Unclear:  
States blinding will 
be maintained by the 
comparison group 
receiving a placebo 
augmentation
NA NA Unclear:
No detail
Inadequate:  
Study suspended
Inadequate: 
GlaxoSmithKline
TORDIA48 Adequate:  
“[U]sing a variation 
of efon’s biased coin 
toss” page 904
Note: The study 
randomized 
participants to an 
SSRi depending on 
what SSRi they were 
already on; ie, it had 
to be a switch to 
another SSRi
Unclear:  
No detail
Adequate:  
The intent was for study participants, 
clinicians, and independent evaluators 
to be blinded to medication treatment 
assignment and for independent 
evaluators to be blinded to CBT 
assignment. Blinding for medication was 
maintained by use of 3 encapsulated 
pills daily for all prescriptions, some of 
which might be placebo to mask drug 
type and dose. The blinding to CBT for 
independent evaluators was maintained 
by scheduling the independent 
evaluator’s assessments at a time not 
contiguous with CBT sessions and 
by asking participants and staff not to 
discuss CBT treatment assignment 
when the independent evaluator 
was present. in 64 cases, the blinding 
of the independent evaluator was 
compromised, most commonly because 
of participant disclosure of receiving 
CBT. Page 904
Inadequate: 
Clinicians did the safety 
assessments and  
“[t]he intent was for 
study participants, 
clinicians, and 
independent evaluators 
to be blinded to 
medication treatment”; 
however they were 
not blind to CBT 
assignment. Page 904. 
Many participants were 
unblinded during the 
continuation phase, 
such that the 24 weeks 
outcomes are affected 
by lack of blinding
Inadequate:  
“The intent was for 
study participants, 
clinicians, and 
independent 
evaluators to 
be blinded 
to medication 
treatment”; however 
they were not blind 
to CBT assignment. 
Page 904
Adequate: 
venlafaxine alone 
22/83 (27%)
venlafaxine + CBT 
30/83 (36% )
SSRi alone 25/85 
(29%)
SSRi + CBT 25/83 
(30%)
Adequate:  
venlafaxine alone  
Side effect: 9
worsening depression: 3
venlafaxine + CBT 
Side effect: 10
worsening depression: 4
SSRi alone  
Side effect: 9
worsening depression: 3
SSRi + CBT  
Side effect: 13
worsening depression: 2
Adequate:
Figure page 903 and table 2 page 
907 indicate all randomized were 
analyzed; with both intent-to-treat 
and observed case data presented. 
State LOCF data were used
Inadequate:  
1. There was a change part way 
through the study from using to 
paroxetine (due to concerns about 
efficacy and safety) to citalopram. 
Of the 50 randomized to receive 
paroxetine only three were in active 
treatment at the time of the change 
and were removed from the study.
2. Did not meet target recruitment 
to satisfy power calculation (required 
400 participants).
3. Baseline characteristics are not 
reported by intervention group; 
authors report no significant 
differences between groups, with the 
exception that the venlafaxine group 
had lower Beck Depression inventory 
score and lower rates of PTSD
Adequate: 
National 
institute of 
Mental Health
Abbreviations: AMi, amitriptyline; CBT, cognitive behavioral therapy; HTA, Health Techology Assessment; LOCF, last observation carried forward; PTSD, posttraumatic 
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Table 2 Risk of bias
Study Randomization 
procedure
Allocation 
concealment
Blinding of outcome  
assessor (efficacy  
outcomes)
Blinding of outcome 
assessor (adverse 
outcomes)
Blinding of 
participants/ 
care givers
Withdrawals n (%) 
in each group
Withdrawals due to 
treatment in each 
group
Intention to treat analysis Other Funding
ADAPT47 Adequate: 
Stochastic 
minimization was 
used to ensure 
balance on 
severity, center, 
sex, comorbid 
behavioral disorder 
(probable or definite 
oppositional defiant 
disorder or conduct 
disorder) and 
age. Page 15 HTA 
report51
Adequate:  
The study psychiatrist 
telephoned an 
independent centre, 
the Department of 
Medical Statistics at 
the Christie Hospital 
in Manchester, for 
randomization.  
Page 15 HTA 
report51
Adequate:  
Outcome assessments were done 
by independent evaluators blind 
to treatment assignment. Specific 
instructions were given to participants, 
parents, and treating clinicians not to 
disclose treatment assignment to the 
blinded evaluator. Page 15 HTA report51
Adequate:  
Adverse events were 
recorded at each 
assessment interview 
(which were conducted 
by blind outcome 
assessors). Page 10 HTA 
report51
Inadequate:  
Study compared 
CBT with non-
CBT, therefore 
participants and 
study clinicians could 
not be blind to 
treatment
Adequate:  
Fluoxetine alone  
week 12: 6/103 (6%) 
week 28: 13/103 
(13%)  
 
Fluoxetine + CBT  
week 12: 11/105 
(10%)  
week 28: 18/105 
(17%)
Unclear:  
Not enough detail 
provided about reasons 
for drop out by group
Inadequate:  
included in primary endpoint 
analysis: Fluoxetine 101/103 
Fluoxetine + CBT 102/105
Unclear:
1. Study psychiatrists delivered 
intervention in both arms so cross 
contamination is possible 
2. Routine care stated to include 
principles of CBT treatment were 
part of routine clinical care; however, 
care mainly took the form of advice, 
rather than collaborative goal setting, 
homework, rewards, and exploration 
and challenging of negative cognitions. 
Sessions were shorter and fewer
3. Precise details of any additional 
routinely offered CAMHS services 
were not systematically assessed
Adequate: 
There was no 
commercial 
sponsorship. 
Page 51 HTA 
report
Birmaher46  Adequate:  
“[R]andomly 
assigned using a 
modification of 
efon’s biased coin 
toss to match 
approximately for 
age and gender.” 
Page 528
Unclear:  
No detail
Adequate:  
Psychiatric research nurse administered 
outcome measurement. “To maintain 
blindness of treatment assignment, the 
research nurse was unaware of the 
results of the side effect evaluations.” 
Page 529
Inadequate:  
The only nonblind 
investigator monitored 
patients’ responses to 
treatment, AMi doses, 
and presence of side 
effects. This investigator 
was not involved in any 
of the ratings of the 
patient.” Page 529
Adequate:  
“After randomization, 
patients received 
identical tablets of 
placebo or AMi. To 
ensure blindness to 
treatment allocation, 
each patient received 
three pills twice a 
day.” Page 528
Adequate:  
AMi: 1/13 (8%) 
Placebo: 5/14 (36% )
Inadequate:  
withdrawn from study 
due to worsening of 
clinical symptoms: AMi: 
1 Placebo: 5 Page 530
Adequate:  
Stated to be done on page 529  
and table 2 includes all participants 
randomized. Note authors also 
undertook completer analysis, 
analysis of patients who completed 
at least 4 weeks of treatment, and 
stated there was no difference 
in outcome. Page 529
Unclear:  
1. Small study 
2. Previous treatment ascertained 
from medical records, raising the 
possibility of incomplete or inaccurate 
information, meaning the population 
may not truly be treatment resistant
Adequate: 
NiMH grant
Robins45 Unclear:  
No detail
Unclear:  
No detail
Unclear:  
States blinding will be maintained by the 
comparison group receiving a placebo 
augmentation
Unclear:  
States blinding will 
be maintained by the 
comparison group 
receiving a placebo 
augmentation
Unclear:  
States blinding will 
be maintained by the 
comparison group 
receiving a placebo 
augmentation
NA NA Unclear:
No detail
Inadequate:  
Study suspended
Inadequate: 
GlaxoSmithKline
TORDIA48 Adequate:  
“[U]sing a variation 
of efon’s biased coin 
toss” page 904
Note: The study 
randomized 
participants to an 
SSRi depending on 
what SSRi they were 
already on; ie, it had 
to be a switch to 
another SSRi
Unclear:  
No detail
Adequate:  
The intent was for study participants, 
clinicians, and independent evaluators 
to be blinded to medication treatment 
assignment and for independent 
evaluators to be blinded to CBT 
assignment. Blinding for medication was 
maintained by use of 3 encapsulated 
pills daily for all prescriptions, some of 
which might be placebo to mask drug 
type and dose. The blinding to CBT for 
independent evaluators was maintained 
by scheduling the independent 
evaluator’s assessments at a time not 
contiguous with CBT sessions and 
by asking participants and staff not to 
discuss CBT treatment assignment 
when the independent evaluator 
was present. in 64 cases, the blinding 
of the independent evaluator was 
compromised, most commonly because 
of participant disclosure of receiving 
CBT. Page 904
Inadequate: 
Clinicians did the safety 
assessments and  
“[t]he intent was for 
study participants, 
clinicians, and 
independent evaluators 
to be blinded to 
medication treatment”; 
however they were 
not blind to CBT 
assignment. Page 904. 
Many participants were 
unblinded during the 
continuation phase, 
such that the 24 weeks 
outcomes are affected 
by lack of blinding
Inadequate:  
“The intent was for 
study participants, 
clinicians, and 
independent 
evaluators to 
be blinded 
to medication 
treatment”; however 
they were not blind 
to CBT assignment. 
Page 904
Adequate: 
venlafaxine alone 
22/83 (27%)
venlafaxine + CBT 
30/83 (36% )
SSRi alone 25/85 
(29%)
SSRi + CBT 25/83 
(30%)
Adequate:  
venlafaxine alone  
Side effect: 9
worsening depression: 3
venlafaxine + CBT 
Side effect: 10
worsening depression: 4
SSRi alone  
Side effect: 9
worsening depression: 3
SSRi + CBT  
Side effect: 13
worsening depression: 2
Adequate:
Figure page 903 and table 2 page 
907 indicate all randomized were 
analyzed; with both intent-to-treat 
and observed case data presented. 
State LOCF data were used
Inadequate:  
1. There was a change part way 
through the study from using to 
paroxetine (due to concerns about 
efficacy and safety) to citalopram. 
Of the 50 randomized to receive 
paroxetine only three were in active 
treatment at the time of the change 
and were removed from the study.
2. Did not meet target recruitment 
to satisfy power calculation (required 
400 participants).
3. Baseline characteristics are not 
reported by intervention group; 
authors report no significant 
differences between groups, with the 
exception that the venlafaxine group 
had lower Beck Depression inventory 
score and lower rates of PTSD
Adequate: 
National 
institute of 
Mental Health
Abbreviations: AMi, amitriptyline; CBT, cognitive behavioral therapy; HTA, Health Techology Assessment; LOCF, last observation carried forward; PTSD, posttraumatic 
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Table 3 Outcome data
Study Response data (CGI = 2) Response data (trial definition) Clinician-rated 
depression
Self-rated 
depression
ADAPT47 12 weeks 
CBT 42/101 (42%)  
No CBT 44/101 (43.5%)  
28 weeks  
CBT 52/98 (53%)  
NO CBT 57/94 (61%)
12 week (HoNOSCA – criteria not defined)  
CBT 97/101 (96%)  
No CBT 99/101 (98%)  
28 weeks (HoNOSCA – criteria not defined)  
CBT 91/98 (93%)  
No CBT 87/95 (92%)
12 weeks CDRS-R  
CBT 42.5 (16.8)  
No CBT 40.0 (13.9)  
28 weeks CDRS-R  
CBT 36.4 (15.3)  
No CBT 34.6 (13.4)
12 weeks MFQ  
CBT 22.7 (15.4)  
No CBT 21.6 (14.8)
28 weeks MFQ  
CBT 18.9 (15.5)  
No CBT 15.5 (15.0)
Birmaher46  10 weeks  
Medication 10/13 (77%) 
Placebo 8/14 (57%)
10 weeks ($ 50% reduction in HDRS)  
Medication 10/13 (77%)  
Placebo 11/14 (79%)
10 week HDRS 
Medication 7.7 (8.0) 
Placebo 8.6 (11.5)
10 week BDi
Medication 10.1 (11.8)
Placebo 10.1 (11.1)
TORDIA48 12 weeks  
CBT 98/166 (59.0%)  
No CBT 80/168 (47.6%)  
24 weeks  
Not reported
12 weeks (CGi #2 + $ 50% improvement in CDRS-R)  
CBT 91/166 (54.8%)  
No CBT 68/168 (40.5%)  
24 weeks  
Not reported
12 weeks CDRS-R  
CBT 36.9 (13.9)  
No CBT 38.1 (12.9)  
24 weeks CDRS-R  
Not reported
12 weeks BDi CBT  
11.0 (11.5) No CBT 
10.5 (9.8)
24 weeks BDi
Not reported
Abbreviations: BDi, Beck Depression inventory; CBT, cognitive behavioral therapy; CDRS-R, Children’s Depression Rating Scale-Revised; HoNOSCA, Health of the 
Nation Outcome Scales for Children and Adolescents; MFQ, Mood and Feelings Questionnaire.
Self-rated depression symptoms
There were no significant differences between the groups 
in self-rated depression severity on the BdI and Mood and 
Feelings Questionnaire (standardized mean difference −0.06, 
95% CI −0.23–0.11) post intervention (see Figure 4), or at 
28-week follow-up in the one trial (AdAPT) in which this 
was reported. The results of the meta-analysis are consistent 
with the way results were reported by the individual studies 
that were included in the meta-analysis with regard to self-
reported depression severity.
Discussion
Principal findings
In our systematic review, we identified only three stud-
ies investigating the management of broadly defined 
treatment-resistant depression in young people. Two of 
these assessed medication and the effect of adding CBT to 
medication. While an assertive trial of medication showed 
some benefit, particularly in one study, neither study nor a 
meta-analysis of data from two trials clearly demonstrated 
an additional benefit of CBT over and above the medica-
tion regimens already in place for any outcome. It should 
be noted that there was no placebo arm in either of these 
studies. The third trial showed no advantage of a tricyclic 
antidepressant over placebo in the context of an inpatient 
admission. The studies were well conducted with a low 
risk of bias, although the TORdIA study did have very 
high dropout rates.48 There were no trials of CBT alone or 
of other psychotherapies, such as interpersonal therapy. 
Overall, there is currently little evidence upon which to 
base clinical decisions about interventions for treatment-
resistant depression in young people.
Strengths and limitations
To our knowledge, no other systematic review or meta-
analysis of interventional studies for treatment of resistant 
depression in children and adolescents has been published. 
We used Cochrane Collaboration methodology,38 which 
ensures clarity and includes an assessment of the possible 
risk of bias in each study included in the review.
We used a broad definition of treatment resistance to 
ensure that we included as many clinically meaningful data 
as possible. However, given the paucity of studies in this 
area, and the variable definitions of treatment resistance that 
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were used in each study, we had to be cautious about how 
we compared the trials in this review.
As is often the case, establishing the most meaningful 
outcome across diverse studies is a challenge. We used the 
CGI criteria as our primary outcomes measure. The CGI scale 
provides a relatively crude estimate of treatment response. 
We used this measure because data based on this definition 
were available from both trials, providing some consistency, 
and because the CGI has been used as a primary outcome 
variable in a number of studies of treatment of depression 
in children and adolescents.42,43 However, because of the 
potential limitations of the measure, we also carried out a 
meta-analysis of response based on the definitions of response 
in the individual trials (CGI plus CdRS-R for the TORdIA 
study, and response on HonOSCA data for the AdAPT 
study). Although there was a more favorable response rate 
in those who received additional CBT in the TORdIA study, 
when findings were aggregated with AdAPT, this finding 
was not supported.
It is of note that the differences reported in the TORdIA 
study are relatively small and not maintained at follow-up 
(according to rates of remission, which were 36.7% in those 
who received additional CBT and 41.1% in those who did 
not. There were also no significant differences on other 
outcomes, there were high dropout rates, and the results 
were not reported according to the groups participants were 
allocated to, but rather according to whether they received 
CBT or not. Therefore, post intervention results with regard 
to response rates should be interpreted cautiously.
Our finding that CBT confers no additional benefit to 
medication is consistent with findings from two previous 
studies of young people with depression (although not classed 
as treatment-resistant).52,53 A randomized effectiveness trial 
of adolescents with major depressive disorder of moderate 
severity, who had recently been prescribed an SSRI, showed 
only weak effects of additional CBT.52 In the Treatment for 
Adolescents with depression Study (TAdS), while the group 
on combined medication and CBT improved more than 
those on either CBT or fluoxetine alone in the short term, 
by 36 weeks there was no difference between groups, and a 
reanalysis of the TAdS data showed that combined treatment 
did not offer any advantage in those participants who were 
most impaired.53
Clinical implications
Unfortunately many young people do not respond to initial 
treatment for depression.19 The move to an assertive trial of 
an antidepressant does appear to lead to benefit, especially 
in the AdAPT trial, although it should be noted that previ-
ous treatment in this trial was predominantly psychosocial.
In the medication only study, Birmaher et al46 hypothesized 
that young people recovered regardless of the group they 
were in due to the effect of removing them from their envi-
ronment into an inpatient setting, potentially decreasing the 
stress they had been experiencing, stating the entire sample 
came from “disorganized and conflict-ridden families.” The 
authors of this trial (Birmaher et al46) also hypothesized that 
the improvement in symptoms that participants in this trial 
experienced might have been due to them receiving positive 
attention from the research nurse who also motivated the 
participants to remain in the study. In the TORdIA study, 
pharmacotherapy   sessions were 30–60 minutes in length and 
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consisted mostly of  safety assessments, but participants also 
received family psychoeducation sessions at the beginning, 
midpoint, and end of the intervention period. In the AdAPT 
trial, which was a pragmatic trial by design, the participants 
were all receiving standard care, which included routine 
monitoring, psychoeducation, support, and encouragement 
to the young person and their families, problem-solving, 
attention to comorbidity, and liaison with schools and social 
workers as required. From these studies, it is impossible to 
know whether CBT on its own may lead to improvement for 
treatment-resistant young people, or whether CBT should be 
started first and medication added if the need arose.
Both the TORdIA study and the study of medica-
tion only46 showed that nonresponse to the interventions 
was predicted by more severe symptoms. Therefore, and 
consistent with guideline recommendations,23 CBT may 
be best reserved for first-line intervention. We propose that 
treatment resistance should be defined as a failure to respond 
to an adequate trial of an evidence-based psychological 
intervention,   followed by a failure to respond to the addition 
of an adequate trial of fluoxetine.
An adequate trial of an intervention such as CBT needs to be 
more clearly articulated. The lack of effectiveness of additional 
CBT shown in the studies included in this review may, for 
example, be due to the “dose” of CBT that was received. Both 
AdAPT and TORdIA comment on the   relatively small number 
of CBT sessions that young people in the study received, 
highlighting that in this population CBT was difficult to 
deliver, and perhaps to receive, in this treatment group. Again, 
a secondary analysis of the   TORdIA dataset showed that those 
who received fewer than nine   sessions of CBT were less likely 
to respond. It has been argued that there is a “dose X technique” 
minimum threshold for the core components of CBT.54 It may 
be that, especially for those with more severe depression, an 
adequate response to medication is required before a young 
person can properly engage in psychotherapy.52,53
Unanswered questions and future 
research
A significant proportion of young people in this study did 
not respond to any treatment.19 In the trial by Birmaher 
et al,46 30%–40% still had symptoms and functional impair-
ment at the end of the trial. Our study shows nonresponse 
rates of 40%–60%. In the AdAPT study, authors suggest 
that from the HonOSCSA scores, nonresponse rates were 
as low as 10%. However, this percentage does not include 
a significant proportion of their participants who had only 
minimal improvement (around 27% at 12 weeks and 22% 
at 28 weeks). It is certainly the case that for a proportion 
of young people, existing evidence-based treatments are 
not   sufficient and new approaches are required.19 There are 
  several avenues that could be pursued further. It is possible 
that younger populations prefer and respond to interven-
tions that have less emphasis on the cognitive components 
of CBT.55 Analysis of the TAdS study suggests that young 
people respond to more simple models of CBT that focus 
on one or two core components, such as behavior activation 
and problem solving.56 A meta-analysis of psychotherapy 
for children and adolescents has shown that “noncognitive” 
aspects of CBT (such as behavioral activation, problem-
  solving, group support, and social skills training) were 
equally effective in treating depression,31 so that targeting of 
specific cognitions may not be necessary.57 Indeed, a second-
ary analysis of data from the TORdIA study showed that CBT 
participants who received the problem-solving and social 
skills component of CBT were more likely to respond.58 It is 
a challenge for the field to decipher the treatment mechanism 
so that the critical aspects of CBT can be delivered.19,54 What 
has not been tested in a pragmatic trial is the effectiveness 
of adding CBT to standard care for young people similar to 
those participants in AdAPT who had severe, complex, and 
persistent depression.
Overall, this review highlights the need for different and 
more effective therapies for depression in young people. 
existing therapies can cure some, and provide some help to 
many, but a disturbing percentage appear to get little relief 
from treatment currently available.
Conclusion
In two well-conducted studies, the addition of CBT to a 
medication regimen offered no benefit over and above the 
medication regimen. Overall, there is a lack of evidence 
about effective interventions to treat young people who have 
failed to respond to evidence-based interventions for depres-
sion. CBT should be reserved for first-line intervention, 
ensuring an adequate dose delivered over an extended period 
of time.23 In order to avert long-term disability associated 
with multiple episodes of illness, or persistent depression, 
research in this area is urgently required. Such studies should 
be distinct from standard maintenance phases in randomized 
controlled trials, and involve re-randomization of treatment 
nonresponders with studies large enough to have power to 
show differences. The challenges of conducting such studies 
are considerable.Psychology Research and Behavior Management 2011:4 submit your manuscript | www.dovepress.com
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